Markets
In this photo illustration, a HIMS logo seen displayed on a...
(Avishek Das/Getty Images)

Hims rises on revenue beat, discloses it’s again in partnership talks with Novo

Hims also disclosed on Monday that it’s in talks with Novo Nordisk to make the drugmaker’s weight-loss drugs available on its platform. Last time, that didn’t go so well.

J. Edward Moreno

Hims & Hers reported third-quarter earnings results that missed Wall Street estimates but revenue that blew expectations out of the water. The company also said its talking with Novo Nordisk again about a potential deal to distribute its branded weight-loss drugs.

The company reported diluted earnings per share of $0.06, less than the $0.09 analysts polled by FactSet were expecting. Hims also reported $598.9 million in sales, significantly more than the $580.2 million the Street was penciling in.

The company narrowed its full-year revenue guidance to about $2.35 billion from between $2.3 billion and $2.4 billion.

Hims also disclosed on Monday that it’s in talks with Novo to make its branded weight-loss drugs available on the telehealth company’s platform. The two previously had a partnership that ended abruptly in June after Novo accused Hims of “illegal mass compounding and deceptive marketing.”

Hims has been looking for ways to spark sales growth as its core sexual health business slows down and its ability to sell weight-loss treatments remains on shaky ground. In recent months, the company has introduced testosterone treatments and menopause regimens, as well as GLP-1 micro-dosing options.

Additionally, the company disclosed that its continuing to explore international expansion in key markets including Brazil, the U.K., Germany, and Australia. Earlier this year, the company acquired a European peer, Zava, for $265.7 million, and announced plans to expand to Canada in 2026 to offer generic versions of Novos weight-loss shot.

Hims said it plans to launch comprehensive lab testing capabilities in the near future. That will support its upcoming longevity specialty as well as its injectable testosterone offerings, both of which it says are coming next year.

More Markets

See all Markets
markets

Palantir pops as its Maven AI targeting system made “official program” for DOD

Palantir jumped Monday following reports that the US military is making official its long-term commitment to buying and using Palantir’s AI-powered data analysis and targeting program.

Reuters’ David Jeans reported over the weekend:

“Palantir’s Maven artificial intelligence system will become an official program of record, Deputy Secretary of Defense Steve ​Feinberg said in a letter to Pentagon leaders, a move that locks in long-term use of Palantir’s weapons-targeting technology across ‌the U.S. military.

In the March 9 letter to senior Pentagon leaders and U.S. military commanders, Feinberg said embedding Palantir’s Maven Smart System would provide warfighters ‘with the latest tools necessary to detect, deter, and dominate our adversaries in all domains.’”

Key benefits of being named an “official program of record” include eligibility for permanent funding from the Department of Defense. The designation also implies a long-term commitment to a technology, which significantly decreases competitive threats from alternate military contractors and vendors.

In other words, being a “program of record” implies significant long-term cash flow in the future from the US Treasury to Palantir, and thus the market reaction.

“Palantir’s Maven artificial intelligence system will become an official program of record, Deputy Secretary of Defense Steve ​Feinberg said in a letter to Pentagon leaders, a move that locks in long-term use of Palantir’s weapons-targeting technology across ‌the U.S. military.

In the March 9 letter to senior Pentagon leaders and U.S. military commanders, Feinberg said embedding Palantir’s Maven Smart System would provide warfighters ‘with the latest tools necessary to detect, deter, and dominate our adversaries in all domains.’”

Key benefits of being named an “official program of record” include eligibility for permanent funding from the Department of Defense. The designation also implies a long-term commitment to a technology, which significantly decreases competitive threats from alternate military contractors and vendors.

In other words, being a “program of record” implies significant long-term cash flow in the future from the US Treasury to Palantir, and thus the market reaction.

markets

Lawmakers to introduce bill banning sports contracts on prediction markets: WSJ

Sports-betting stocks rose after The Wall Street Journal reported that a bipartisan pair of lawmakers are seeking to ban Commodity Futures Trading Commission-regulated companies from offering sports-related contracts on prediction markets.

Reportedly sponsored by Sens. Adam Schiff, D-Calif., and John Curtis, R-Utah, the bill would prevent companies like Kalshi or Polymarket’s US arm from posting event contracts related to the outcome of sporting events, a market that accounts for a sizable chunk of their volumes.

Prediction markets have emerged as competitors to sports-betting platforms, which are primarily regulated at the state level, and companies like DraftKings and Flutter Entertainment have risen on the news in premarket trading.

Meanwhile, Robinhood Markets and Interactive Brokers, which both offer prediction markets covering sports and other contracts, ticked down on the news before President Trump’s latest Iran announcement sent much of the stock market jolting higher, with futures on the S&P 500 rising more than 3% in a matter of minutes.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions. I own Robinhood stock as part of my compensation. Event contracts are offered through Robinhood Derivatives, LLC — probabilities referenced or sourced from KalshiEx LLC or ForecastEx LLC.)

Prediction markets have emerged as competitors to sports-betting platforms, which are primarily regulated at the state level, and companies like DraftKings and Flutter Entertainment have risen on the news in premarket trading.

Meanwhile, Robinhood Markets and Interactive Brokers, which both offer prediction markets covering sports and other contracts, ticked down on the news before President Trump’s latest Iran announcement sent much of the stock market jolting higher, with futures on the S&P 500 rising more than 3% in a matter of minutes.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions. I own Robinhood stock as part of my compensation. Event contracts are offered through Robinhood Derivatives, LLC — probabilities referenced or sourced from KalshiEx LLC or ForecastEx LLC.)

markets

Synopsys rises on WSJ report of Elliott’s new multibillion-dollar stake

Software company Synopsys is up 3% in premarket trading on Monday after The Wall Street Journal reported that Elliott Investment Management, a well-known activist fund, has taken a multibillion-dollar stake in the company.

Elliott Managing Partner Jesse Cohn told the WSJ that “Synopsys is essential to the global chip industry,” and that it is “uniquely positioned to benefit” as the AI industry continues to require more capital, more complex chips, and therefore, more software to design them.

The firm’s investment is predicated on a “clear opportunity for Synopsys’ financial performance to more fully reflect the value it delivers.” While memory stocks like Micron have been on a tear recently, Synopsys has dropped 8% over the past year, lagging behind its biggest rival, Cadence Design Systems, which is up 6% in the same period.

Citing people familiar with the investment in Synopsys, the Journal reports that Elliott sees room for the company to boost sales and improve its margins to be more in line with that of Cadence. In its fiscal year 2025, Cadence notched an adjusted operating margin of nearly 45%, while Synopsys eked out only 37%.

Elliott Managing Partner Jesse Cohn told the WSJ that “Synopsys is essential to the global chip industry,” and that it is “uniquely positioned to benefit” as the AI industry continues to require more capital, more complex chips, and therefore, more software to design them.

The firm’s investment is predicated on a “clear opportunity for Synopsys’ financial performance to more fully reflect the value it delivers.” While memory stocks like Micron have been on a tear recently, Synopsys has dropped 8% over the past year, lagging behind its biggest rival, Cadence Design Systems, which is up 6% in the same period.

Citing people familiar with the investment in Synopsys, the Journal reports that Elliott sees room for the company to boost sales and improve its margins to be more in line with that of Cadence. In its fiscal year 2025, Cadence notched an adjusted operating margin of nearly 45%, while Synopsys eked out only 37%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.